GLP-1 medications have rapidly become one of the most discussed developments in modern medicine. Originally designed to help manage Type 2 diabetes, these drugs are now being studied for a growing list of potential health benefits, including cardiovascular protection, liver disease treatment and even cancer prevention. While the results are encouraging, Canadian researchers say the evidence is still evolving and far from definitive.
Expanding Benefits Beyond Diabetes and Weight Loss
GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone that helps regulate blood sugar levels. It stimulates insulin production, slows digestion and sends signals to the brain that reduce appetite and food cravings.
Medications known as GLP-1 receptor agonists mimic this hormone. Common examples include semaglutide, liraglutide and tirzepatide. Semaglutide is widely recognized through the medications Ozempic and Wegovy.
Over the past several years, research has demonstrated that these drugs offer benefits extending well beyond blood sugar control. Large clinical trials have shown they can help people with Type 2 diabetes manage their condition, support significant weight loss and lower the risk of heart attacks, strokes and cardiovascular-related deaths.
Proven Health Benefits
According to Dr. Daniel Drucker, the Canadian scientist whose pioneering work helped lay the foundation for today’s GLP-1 therapies, there is now strong evidence supporting several medical uses for the drugs.
Studies have shown that GLP-1 medications can:
- Improve blood sugar control in people with Type 2 diabetes.
- Support sustained weight reduction.
- Reduce the risk of major cardiovascular events.
- Lower rates of metabolic liver disease.
- Help protect kidney function in people with diabetes.
- Reduce the severity of obstructive sleep apnea.
- Improve outcomes for people with peripheral artery disease.
- Ease pain associated with certain forms of arthritis.
Despite the growing list of benefits, Drucker cautions against viewing these medications as a universal solution.
“Should we put these medicines in the drinking water? Should everybody take them? No, not yet,” he said.
“But we are accumulating a substantial body of evidence for disorders where the medicines have benefit — and we’re also learning where the medicines have no benefit — and that’s what guides us in evidence-based medicine.”
Researchers Explore Links to Cancer Prevention
One of the most closely watched areas of GLP-1 research involves cancer.
Cancer remains the leading cause of death in Canada, and statistics indicate that more than 40 per cent of Canadians will develop some form of cancer during their lifetime. As a result, any treatment that could lower cancer risk attracts significant attention from researchers and health-care professionals.
Recent studies presented at a major international oncology conference have added to growing evidence that GLP-1 medications may influence cancer outcomes.
Studies Suggest Reduced Risk and Disease Progression
One study examined more than 10,000 patient records and found that cancer patients using GLP-1 medications experienced substantially lower rates of disease progression across several tumour types.
Researchers observed some of the strongest effects in breast, liver and colorectal cancers, as well as a particular form of lung cancer. Notably, some of the benefits appeared in cancers that are not typically associated with obesity, suggesting additional biological mechanisms may be involved.
A separate study involving approximately 110,000 women found that patients taking GLP-1 medications were up to 35 per cent less likely to develop breast cancer than those who did not use the drugs.
These findings have generated optimism, but experts stress that the research largely reflects associations observed in patient data rather than direct proof that the medications prevent cancer.
Why Scientists Remain Cautious
While the emerging evidence is promising, researchers emphasize that more rigorous clinical trials are needed before GLP-1 medications can be recommended specifically for cancer prevention.
Many current studies rely on health records and observational data. Such research can identify patterns and associations, but it cannot always determine cause and effect.
Scientists are also investigating whether the apparent cancer benefits stem primarily from weight loss and improved metabolic health or whether GLP-1 drugs have direct effects on tumour growth and inflammation.
Beyond cancer, researchers continue exploring the medications’ potential role in treating inflammatory diseases such as Crohn’s disease, ulcerative colitis, skin disorders and certain lung conditions.
There is also growing interest in whether GLP-1 therapies could help reduce substance-use disorders by influencing the same reward pathways that affect appetite and cravings.
The Bottom Line
GLP-1 medications have already transformed the treatment of Type 2 diabetes and obesity, while delivering clear benefits for cardiovascular, liver and kidney health. Early research also suggests they may help reduce cancer risk and slow disease progression in some patients.
However, health experts say it is still too early to conclude that everyone should be taking these drugs. As additional clinical trials are completed, researchers hope to better understand who benefits most, where the medications are most effective and where their limitations lie. For now, the growing promise of GLP-1 therapies is matched by the need for careful, evidence-based evaluation.
American author Nolan Fraser crafts stories that balance entertainment with meaningful exploration of life’s challenges and opportunities. His work reflects a passion for storytelling and a commitment to creating memorable literary journeys.